Adherence to antiretroviral therapy: The more you look, the more you see

Current Opinion in HIV and AIDS

Volumn 4, Issue 6, 2009, Pages 488-492

  Taiwo, Babafemi ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adherence; HIV; Treatment partners

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMPUTER MODEL; DEPRESSION; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; MEDICAL RESEARCH; OUTPATIENT; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS; PATIENT COMPLIANCE; SALVAGE THERAPY; TREATMENT OUTCOME; VIRAL LOAD;

EID: 70350162461     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283311058     Document Type: Review

References (84)

1. Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis 2007; 45:1377-1385.
2. Bardequez AD, Lindsey JC, Shannon M, et al. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr 2008; 48:408-417.
3. Lima VD, Harrigan R, Murray M, et al. Differential impact of adherence on longterm response among naive HIV-1 infected individuals. AIDS 2008; 22: 2371-2380.
4. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146:564-573.
5. Podsadecki TJ, Vrijens BC, Tousset EP, et al. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis 2007; 196:1773-1778.
6. Metzner KJ, Stefano GG, Knoepfel A, et al. Minority quasispecies of drug resistant HIV-1 that lead to early therapy failure in treatment- näíve and: adherent patients. Clin Infect Dis 2009; 48:239-247.
7. Bisson GP, Rowh A, Weinstein R, et al. Antiretroviral failure despite high levels of adherence-response relationship in Botswana. J Acquir Immune Defic Syndr 2008; 49:107-110.
8. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-941.
9. Shuter J, Sarlo JA, Kanmaz TJ, et al. HIV-infected patients receiving lopinavir/ ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates below 95%. J AIDS 2007; 45:4-8.
10. Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 2008; 47:384-390.
11. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection. 2008 Recommendations of the International AIDS Society-USA Panel. JAMA 2008; 300:555-570.
12. Braithwaite RS, Roberts MS, Goetz MB, et al. Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence? Clin Infect Dis 2009; 48:822-826.
13. Lattuada E, Lanzafame M, Gottardi M, et al. Initial hospitalization and adherence to highly active antiretroviral therapy (Letter). Clin Infect Dis 2008; 46:957-958.
14. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
15. Parienti J., Das-Douglas M., Massari V. et al. Not all missed doses are the same: Sustained NNRTI interruptions predict HIV rebound at low-to-moderate adherence levels
16. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 13:853.
17. Sterne JA, HernanMA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366:378.
18. Hogg R, Lima A, Sterne JA, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-299.
19. US Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. http:// aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
20. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society - USA panel. JAMA 2008; 300:555-570.
21. Saag, M, Heera, J, Goodrich, J, et al. Reanalysis of the MERIT study with the enhanced Trofile assay (MERIT-ES) [abstract H-1232a]. Program and abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting; 25-28 October 2008; Washington, DC.
22. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-näíve patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133.
23. Lennox J, Dejesus E, Lazzarin A, et al. Subgroup analyses from STARTMRK, a Phase III study of raltegravir-based versus efavirenz-based combination therapy in treatment-naive HIV-infected patients [abstract 573]. Presented at the 16th Annual Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada.
24. Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral näíve patients. I.CO.N.A. study group. Italian cohort of antiretroval-näíve patients. AIDS 2000; 14:499-507.
25. Mocroft A, Youle M, Moore A, et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS 2001; 15:185-194.
26. Mocroft A, Phillips AN, Soriano V. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005; 21:527-536. (Pubitemid 40944314)
27. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz or both drugs plus stavudine and lamivudine: a randomized open-label trial, the 2NN study. Lancet 2004; 363:1253-1263.
28. Mallal S, Phillips E, Carosi G, et al. HLA-B-5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
29. Brinkman K, ter Hofstede HJ. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev 1999; 1:141-148.
30. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.
31. Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1 associated nephropathy: a 12 year cohort study. AIDS 2004; 18:541-546.
32. De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in highly treatment experienced HIV-1-infected patients: a randomized openlabel noninferiority trial, EASIER-ANRS 138 [abstract 572]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec.
33. Eron J, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate noninferior virologic efficacy at week 24 [abstract 70aLB]. 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Quebec.
34. Fletcher CV, Acosta EP, Cheng H, et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS 2000; 14:2495-2501.
35. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers. ACTG study A5047. AIDS 2002; 16:569-577.
36. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA 2005; 293:817-829.
37. Garcia-Gasco P,Maida I, Blanco F, et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother 2008; 61:699-704.
38. Petersen ML, van der Laan MJ, Napravnik S, et al. Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22:2097-2106.
39. Reynolds SJ, Kityo C, Mbamanya F, et al. Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. Antivir Ther 2009; 14:293-297.
40. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drugresistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.
41. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-näíve HIV-1 infected subjects. J Infect Dis 2008; 197:867-870.
42. von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment. Arch Intern Med 2007; 167:1782-1790.
43. Gupta R,Hill A, SawyerAW, Pillay D. Emergence of drug resistance in HIV type-1 infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47:712-722.
44. Gulick RM, Ribaudo HJ, Shikuma CM, et al. ACTG 5095: three vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection - a randomized clinical trial. JAMA 2007; 296:769-781.
45. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: 3-year randomized trial. JAMA 2004; 292:191-201.
46. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106.
47. Cassetti L, Madruga JV, Enjosea J, 903 Study team. The safety and efficacy of Tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) in antiretroviral-näíve patients through seven years [abstract TUPE0057]. Presented at the XVII International AIDS Conference; 2008; Mexico City, Mexico.
48. Gallant JE, DeJesus E, Arribas JR, Pozinak AL, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine and efavirenz for HIV. N Engl J Med 2006; 354:251-260.
49. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu-Natal, South Africa. Clin Infect Dis 2008; 46:1589-1597.
50. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-452.
51. Humphreys EH, Hernandez LB, Rutherford GW. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev 2007:CD006517.
52. Chetchotisakd P, Anunnatsiri S, Mootsikapun P, et al. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. HIV Med 2007; 8:529-535.
53. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir- ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatmentexperienced, HIV-infected patients in TITAN: a randomized controlled phase III trial. Lancet 2007; 370:49.
54. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-1: 24- week results from a randomized, double-blind, placebo-controlled trial. Lancet 2007; 370:29-38.
55. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24- week results from a randomized, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
56. Vingerhoets J, Peeters M, Azijn H, et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine: multivariate analysis on the pooled DUET-1 and DUET-2 clinical trial data [abstract 24]. 17th International HIV Drug Resistance Workshop; Antiviral Therapy, Vol.14, Supplement 1, 2008.
57. Marcelin A, Flandre P, Descamps D, et al. Factors associated with early virological response to etravirine in NNRTI-experienced HIV-infected patients [abstract 645]. Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada.
58. MacArthur RD, Novac R, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of nonnucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368:2125-2135.
59. Condra JH, Petropoulos CJ, Ziermann R, et al. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis 2000; 182:758-765.
60. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002; 346:2039-2046.
61. Eron J, Yeni P, Gathe J, et al. The KLEAN study of fosamprenavir- ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised noninferiority trial. Lancet 2006; 368:476-482.
62. Gathe JC, Ive P, Wood R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/Ritonavir versus twice-daily Nelfinavir in näíve HIV-1-infectred patients. AIDS 2004; 18:1529-1537.
63. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009; 50:367-374.
64. Ortiz R, DeJesus E, Khanlou H, et al. Efficacy and safety of once daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 2008; 22:1389-1397.
65. Smith K, Fine DM, Bellos NC, et al. Similarity in efficacy and safety of Abacavir/ lamivudine (ABC/3TC) compared to Tenofovir/emtricitabine (TDF/FTC) in combination with QD lopinavir/Ritonavir (LPV/r) over 96 weeks in the HEAT study [abstract LBPE1138]. Presented at the XVII International AIDS Conference; 2008; Mexico City, Mexico.
66. Molina J-M, Andrade-Villanueva J, Echavarria J, et al. Once-daily atazanavir/ ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-injfected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
67. Gathe J, Cooper DA, Farthing C, et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin Infect Dis 2006; 43:1337.
68. Cahn P, Villacian J, Lazzarin A, et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis 2006; 43:1347.
69. Walmsley S, Cotte L, Ruscoin S, Ward DJ, et al. Treatment responses to ritonavir-boosted tipranavir versus ritonavir boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores. J AIDS 2007; 21:2245-2248.
70. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomized trials. Lancet 2007; 369:1169-1178. Parienti J, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One 2008; 3:e2783. doi:10.1371/journal.pone. 0002783.
71. Gardner EM, Sharma S, Peng G, et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008; 22:75-82.
72. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairments, and adherence to highly active antiretroviral therapy among HIV-infected persons. Psychosomatics 2004; 45:394-402.
73. Bouhnik AD, Preau M, Vincent E, et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antiv Ther 2005; 10:53-61.
74. Nachega JB, Hislop M, Nguyen H, et al. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in Southern Africa. J Acquir Immune Defic Syndrome 2009; 51: 65-71.
75. Reisner SL, Mimiaga MJ, Skeer M, et al. A review of antiretroviral adherence and intervention studies among HIV-infected youths. Top HIV Med 2009; 17:14-25.
76. Schackman BR, Ribaudo HJ, Krambrink A, et al. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy. J Acquir Immune Defic Syndr 2007; 46:547-554.
77. Simoni JM, Amico KR, Pearson CR, Mallow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep 2008; 10:515-521.
78. Petersen M, Wang Y, van der Laan M, et al. Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis 2007; 45:908-915.
79. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis 2007; 45:1492-1498.
80. Birbeck GL, Chomba E, Kvalsund M, et al. Antiretroviral adherence in rural Zambia: the first year of treatment availability. Am J Trop Med Hyg 2009; 80:669-674.
81. Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS 2004; 18 (Suppl 3): S21-S25.
82. Sarna A, Luchters S, Geibel S, et al. Short- and long-term efficacy of modified directly observed antiretroviral therapy treatment in Mombasa, Kenya: a randomized trial. J Acquir Immune Defic Syndr 2008; 48:611-619.
83. Taiwo BO, Idoko J, Otoh I, et al. (2008) Patient-selected treatment partner is associated with superior virologic response to first-line HAART in Jos, Nigeria. In: proceedings of 3rd International Conference on Treatment Adherence. Jersey City, New Jersey, USA. http://www.iapac.org/ AdherenceConference/ AdherenceConfPrg-Links.pdf.
84. Nachega J, Goliath R, Efron A, et al. Randomized trial of trained patientnominated treatment supporters providing directly observed ART in South African adults initiating HIV therapy [Oral abstract #143]. In: proceedings of 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February, 2009; Montreal, Canada.